Academic Interests
Her expertise is in perinatal pharmacoepidemiology and pharmacotherapy in pregnancy and breastfeeding. She has studied risks of prenatal exposure to medication on immediate pregnancy outcome (e.g. birth weight, malformations) and long term outcomes such as neurodevelopmental disorders and childhood cancer.
She has a PhD in pharmacoepidemiology and pharmacotherapy on drug use during pregnancy, Faculty of Medicine, University of Oslo in 2005. MSc Pharm in 1997. Dr. Nordeng became a full professor at the Faculty of Mathematics and Natural Sciences in 2011.
She has a long track record of interdisciplinary research and of international research projects, using large population-based cohorts and linked health care registries, especially in the Nordic countries. She was awarded an ERC StG for the project “DrugsInPregnancy” and is currently the head of an International Partnerships for Excellent Education, Research and Innovation on genetic pharmacoepidemiology (iAPOGEE) and head of the UiOLifeScience convergence environment UIORealArt: Real world – artificial worlds: Improving causal inference in perinatal pharmaco-epidemiology using machine learning approaches on real-world and artificial data. Over the past years, she has put great efforts into creating a data analytical pipeline at the University of Oslo for rapid analysis of urgent perinatal pharmacovigilance signals.
Dr. Nordeng is the editor of a textbook in clinical pharmacology for nurses and has authored over 200 scientific articles, book chapters and clinical guidelines, many of which focus on perinatal drug use and safety. She is currently responsible for recommendation about medication safety in pregnancy and breast feeding in Norwegian Drug Formulary (http://legemiddelhandboka.no/).
In 2023, she was awarded the Women's Research Award from the Norwegian Women's Public Health Association, Norway's largest women's organization, for her research to improve women’s health. In 2016 she was awarded Pharmacist of the Year in Norway and in 2017 she was awarded the Titan prize for excellence in science dissemination by the UiO.
As of 2018, she has been an EU commission appointed independent scientific expert member of PRAC, European Medicines Agency. She is a member of NorPEN (Nordic Pharmacoepidemiology Network) and a fellow of the International Society of Pharmacoepidemiology (FISPE). As of 2024, she holds a position as adjunct Professor in Clinical Pharmacology at the Faculty of Health Sciences, University of Southern Denmark.
Teaching
- FARM1120 – Pharmacist, Patient and Society
- FARM3120 – Medicines Use and Public Health
- FRM 4040 - Social science methodology to be prepared for research in Social pharmacy
- FRM5020 – Pharmaceutical research project - University of Oslo
- FRM 5630 - Use of Medicines in a Global Society
- FRM5640 –Pharmacoepidemiology study design and manuscript writing
- FRM9915 - NFIF - Introduction to and Application of Propensity Scores
Higher education and employment history
- Professor, perinatal pharmacoepidemiology and social pharmacy, Department of pharmacy, University of Oslo, Norway, 2011 – present
- Adjunct Professor in Clinical Pharmacology at the Faculty of Health Sciences, University of Southern Denmark, 2024 -
- Researcher, The Norwegian Institute of Public Health (NIPH), Division of Child Health and Development, 20% position, 2005 – present
- Associate professor, Department of pharmacy, University of Oslo, Norway, 2007 – 2011
- Department of Pharmacotherapeutics, Medical faculty, University of Oslo, Norway. Post doctoral position conducting research on drug safety on pregnancy, 2005 – 2007
- Regional Drug Information centre. Part time position as advisor in pharmacovigilance work and counselling healthcare personnel in pharmacotherapeutical issues. 2005.
- Doctorial work (dr. philos). Department of Pharmacotherapeutics, Medical faculty, University of Oslo, Norway. 1999 – 2004. Thesis on “Drug use in pregnancy and after delivery” with special focus on factors predicting drug use illness during pregnancy.
- MSc in Pharmacy, School of Pharmacy, University of Oslo, Norway, 1997. Masters in analytical chemistry.
Appointments
- Head of PharmaSafe Research Group at the Department of Pharmacy
- Head of UiORealArt convergence environment at UIO, 2022 - 2026
- Head of iAPOGEE, International Partnerships for Excellent Education, Research and Innovation on genetic pharmacoepidemiolog, 2022 - 2026
- Head of PharmaTox Strategic Research Enviroment at MatNat from 2015 - 2024
- Head of Norwegian PhD School in Pharmacy 2015 - 2021
- FISPE, fellow of the International Society of Pharmacoepidemiology
- Member of Scientific Board Norwegian Pharmaceutical Journal, 2008 - 2018
- Member of the Editorial board: Journal of Population Therapeutics and Clinical Pharmacology, 2012 - 2018
- Board member, National Council for ranking journals in Pharmacology, Toxicology, Pharmacy, 2010 - present
- Mentor, Career Development Program for female post doc fellows at UiO, 2013
Cooperation
- Division of Child Health and Development, National Institute of Public Health
- Faculty of Health Sciences, University of Southern Denmark
- Genetics Dpt., Biosciences Institute, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
-
Center for Better Beginnings, School of Medicine, University of California, San Diego
- Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Center, Nijmegen
- Department of Epidemiology, Biostatistics, and Occupational Health (EBOH), McGill University, Canada
- Team Pharmacoepidemiology, Inserm U1219 Research Center Bordeaux Population Health, University of Bordeaux, France